EFFECTIVENESS AND COVERAGE OF PNEUMOCOCCAL AND RSV VACCINES IN REDUCING CHILDHOOD PNEUMONIA HOSPITALIZATIONS
DOI:
https://doi.org/10.5281/zenodo.18264798Abstract
Childhood pneumonia remains one of the leading causes of morbidity, hospitalization, and mortality among children under five years of age worldwide. Lower respiratory tract infections account for a substantial proportion of pediatric hospital admissions, particularly in low- and middle-income countries. Streptococcus pneumoniae and respiratory syncytial virus (RSV) are among the most significant etiological agents responsible for severe disease. Vaccination represents the most effective preventive strategy. This thesis evaluates the effectiveness and coverage of pneumococcal and RSV vaccines in reducing childhood pneumonia-related hospitalizations based on international clinical, epidemiological, and public health evidence.
References
World Health Organization. Pneumonia: Key facts. Geneva: WHO; 2024.
Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape. Lancet Infect Dis. 2020;20(10):e7–e15.
Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86:408–416.
Shi T, McAllister DA, O'Brien KL, et al. Global burden of RSV-associated lower respiratory tract infection. Lancet. 2017;390:946–958.
Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease. J Infect Dis. 2010;201(1):32–41.
Weinberger DM, Grant LR, Steiner CA, et al. Reduced hospitalizations after PCV introduction. MMWR. 2014;63(44):995–998.
Griffin MP, Yuan Y, Takas T, et al. Nirsevimab for prevention of RSV. N Engl J Med. 2020;383:415–425.
Madhi SA, Polack FP, Piedra PA, et al. Maternal RSV vaccination. N Engl J Med. 2020;383:426–439
